Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

NCT03331289 on ClinicalTrials.gov · last registry update 2023-07-24

Finished 31 March 2022, after enrolling 107 people. Primary outcome, as filed: Change in EGP From Baseline to Post-oral Glucose Load. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: The University of Texas Health Science Center at San Antonio
Sponsor type: Other
Enrollment: 107
Started: 2018-02-28
Primary completion: 2022-03-31 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in EGP From Baseline to Post-oral Glucose Load.

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.